Cero Therapeutics Files 8-K for Other Events

TL;DR

Cero Therapeutics filed an 8-K for 'Other Events' on Jan 17th. Details TBD.

AI Summary

Cero Therapeutics Holdings, Inc. filed an 8-K on January 21, 2025, reporting an event that occurred on January 17, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, acquisitions, or executive changes. The company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021, is incorporated in Delaware and operates in the Biological Products sector.

Why It Matters

This filing indicates a routine update or event for Cero Therapeutics, but without specific details, its immediate market impact is unclear.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosure of significant financial or operational changes.

Key Players & Entities

• CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
• January 17, 2025 (date) — Earliest event date
• January 21, 2025 (date) — Filing date
• Phoenix Biotech Acquisition Corp. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CERO NASDAQ Global Market
• $50 million — any has not been in compliance with the $50 million minimum Market Value of Listed Securiti
• $15 million — quirement (the "MVLS Requirement"), the $15 million minimum Market Value of Publicly Held S
• $1.00 m — ement (the "MVPHS Requirement") and the $1.00 minimum Bid Price requirement (the "Bid P
• $2.5 million — t, which permits companies to satisfy a $2.5 million minimum stockholders' equity requiremen
• $1 million — eu of the MVLS Requirement, and a lower $1 million MVPHS Requirement, completing a reverse
• $1.00 — s common stock on Nasdaq has been above $1.00 on each trading day following such reve

Filing Documents

• ea0228123-8k_cerotherap.htm (8-K) — 28KB
• 0001213900-25-004756.txt ( ) — 243KB
• cero-20250117.xsd (EX-101.SCH) — 4KB
• cero-20250117_def.xml (EX-101.DEF) — 26KB
• cero-20250117_lab.xml (EX-101.LAB) — 36KB
• cero-20250117_pre.xml (EX-101.PRE) — 25KB
• ea0228123-8k_cerotherap_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events. On January 17, 2025, CERo Therapeutics Holdings, Inc. (the "Company") received a letter setting forth the determination of a panel convened by Nasdaq (the "Nasdaq Panel") granting the Company's request for an extension (the "Extension") to regain compliance with certain continued listing requirements of the Nasdaq Stock Market until April 22, 2025 (the "Extension Date"). The Company presented its plan (the "Plan") for regaining compliance with such requirements at a hearing conducted on December 17, 2025. As previously disclosed, the Company has not been in compliance with the $50 million minimum Market Value of Listed Securities requirement (the "MVLS Requirement"), the $15 million minimum Market Value of Publicly Held Securities requirement (the "MVPHS Requirement") and the $1.00 minimum Bid Price requirement (the "Bid Price Requirement"). All applicable automatic grace periods for regaining compliance for such requirements have expired. The Company's Plan includes transferring the listing of its securities to the Nasdaq Capital Market, which permits companies to satisfy a $2.5 million minimum stockholders' equity requirement in lieu of the MVLS Requirement, and a lower $1 million MVPHS Requirement, completing a reverse stock split to regain compliance with the Bid Price Requirement and certain capital raising activities to attain such $2.5 million of stockholders' equity. The Extension is subject to certain conditions, including that the Company regain compliance with the Bid Price Requirement and apply to transfer the listing of its securities to the Nasdaq Capital Market by January 22, 2025, as well as the provision of certain information prior to the Extension Date. The Company effected a reverse stock split at a 100 to 1 ratio prior to the open of trading on January 8, 2025 and the closing price of its common stock on Nasdaq has been above $1.00 on each trading day following such reverse stock split. The Company expects to submit t

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR